<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p153" style="overflow: hidden; position: relative; background-color: white; width: 1210px; height: 935px;">
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<style type="text/css" >

#t1_153{left:35px;bottom:24px;letter-spacing:-0.34px;word-spacing:0.13px;}
#t2_153{left:306px;bottom:30px;}
#t3_153{left:313px;bottom:24px;letter-spacing:0.16px;}
#t4_153{left:346px;bottom:30px;}
#t5_153{left:351px;bottom:24px;letter-spacing:-0.16px;word-spacing:-0.22px;}
#t6_153{left:517px;bottom:30px;}
#t7_153{left:524px;bottom:24px;letter-spacing:-0.28px;word-spacing:-0.09px;}
#t8_153{left:288px;bottom:860px;letter-spacing:0.11px;word-spacing:-0.55px;}
#t9_153{left:288px;bottom:829px;letter-spacing:0.27px;word-spacing:-0.69px;}
#ta_153{left:1115px;bottom:27px;letter-spacing:0.23px;}
#tb_153{left:35px;bottom:777px;letter-spacing:0.14px;word-spacing:-1.19px;}
#tc_153{left:362px;bottom:777px;}
#td_153{left:378px;bottom:777px;letter-spacing:0.1px;word-spacing:0.08px;}
#te_153{left:35px;bottom:754px;letter-spacing:0.06px;word-spacing:0.13px;}
#tf_153{left:35px;bottom:731px;letter-spacing:0.14px;}
#tg_153{left:163px;bottom:738px;letter-spacing:-0.01px;}
#th_153{left:186px;bottom:731px;letter-spacing:0.13px;word-spacing:0.06px;}
#ti_153{left:35px;bottom:707px;letter-spacing:0.08px;word-spacing:0.11px;}
#tj_153{left:35px;bottom:684px;letter-spacing:0.04px;word-spacing:-0.86px;}
#tk_153{left:35px;bottom:661px;letter-spacing:0.1px;word-spacing:0.09px;}
#tl_153{left:35px;bottom:638px;letter-spacing:0.04px;word-spacing:0.14px;}
#tm_153{left:35px;bottom:599px;letter-spacing:0.1px;word-spacing:-1.04px;}
#tn_153{left:35px;bottom:575px;letter-spacing:0.03px;word-spacing:0.16px;}
#to_153{left:35px;bottom:552px;letter-spacing:0.02px;word-spacing:0.17px;}
#tp_153{left:35px;bottom:529px;letter-spacing:-0.02px;word-spacing:0.21px;}
#tq_153{left:280px;bottom:529px;}
#tr_153{left:297px;bottom:529px;letter-spacing:0.24px;word-spacing:-0.06px;}
#ts_153{left:352px;bottom:536px;letter-spacing:-0.01px;}
#tt_153{left:375px;bottom:529px;letter-spacing:0.15px;word-spacing:0.03px;}
#tu_153{left:35px;bottom:506px;letter-spacing:0.11px;word-spacing:0.08px;}
#tv_153{left:35px;bottom:482px;letter-spacing:0.15px;word-spacing:-1.2px;}
#tw_153{left:482px;bottom:482px;}
#tx_153{left:496px;bottom:482px;letter-spacing:0.1px;word-spacing:-0.75px;}
#ty_153{left:35px;bottom:459px;letter-spacing:0.14px;word-spacing:0.05px;}
#tz_153{left:477px;bottom:459px;}
#t10_153{left:493px;bottom:459px;letter-spacing:0.27px;word-spacing:-0.09px;}
#t11_153{left:35px;bottom:436px;letter-spacing:0.1px;word-spacing:0.09px;}
#t12_153{left:35px;bottom:413px;letter-spacing:0.06px;word-spacing:0.13px;}
#t13_153{left:35px;bottom:390px;letter-spacing:0.17px;word-spacing:-0.28px;}
#t14_153{left:35px;bottom:366px;letter-spacing:0.16px;word-spacing:0.03px;}
#t15_153{left:35px;bottom:343px;letter-spacing:0.1px;word-spacing:-0.88px;}
#t16_153{left:35px;bottom:320px;letter-spacing:0.08px;word-spacing:0.11px;}
#t17_153{left:35px;bottom:297px;letter-spacing:0.14px;}
#t18_153{left:35px;bottom:258px;letter-spacing:-0.19px;word-spacing:0.61px;}
#t19_153{left:35px;bottom:234px;letter-spacing:-0.01px;word-spacing:-0.62px;}
#t1a_153{left:35px;bottom:211px;letter-spacing:0.12px;word-spacing:0.07px;}
#t1b_153{left:35px;bottom:188px;letter-spacing:0.1px;word-spacing:-0.71px;}
#t1c_153{left:35px;bottom:165px;letter-spacing:0.11px;word-spacing:-0.85px;}
#t1d_153{left:318px;bottom:165px;letter-spacing:0.2px;}
#t1e_153{left:548px;bottom:165px;letter-spacing:0.17px;word-spacing:0.01px;}
#t1f_153{left:35px;bottom:141px;letter-spacing:0.14px;word-spacing:0.05px;}
#t1g_153{left:35px;bottom:118px;letter-spacing:0.08px;word-spacing:0.11px;}
#t1h_153{left:35px;bottom:95px;letter-spacing:0.01px;word-spacing:-0.59px;}
#t1i_153{left:35px;bottom:72px;letter-spacing:0.17px;word-spacing:0.01px;}
#t1j_153{left:618px;bottom:777px;letter-spacing:0.02px;word-spacing:0.17px;}
#t1k_153{left:618px;bottom:754px;letter-spacing:0.19px;word-spacing:-0.01px;}
#t1l_153{left:618px;bottom:713px;word-spacing:-0.77px;}
#t1m_153{left:618px;bottom:690px;letter-spacing:0.06px;word-spacing:-0.57px;}
#t1n_153{left:618px;bottom:667px;letter-spacing:0.12px;word-spacing:0.07px;}
#t1o_153{left:618px;bottom:645px;letter-spacing:0.1px;word-spacing:-1.15px;}
#t1p_153{left:618px;bottom:622px;letter-spacing:0.07px;word-spacing:0.12px;}
#t1q_153{left:618px;bottom:599px;letter-spacing:0.14px;word-spacing:0.04px;}
#t1r_153{left:618px;bottom:575px;letter-spacing:0.04px;word-spacing:0.15px;}
#t1s_153{left:618px;bottom:552px;letter-spacing:0.06px;word-spacing:0.13px;}
#t1t_153{left:618px;bottom:529px;letter-spacing:0.01px;word-spacing:-1.05px;}
#t1u_153{left:618px;bottom:506px;letter-spacing:0.09px;word-spacing:0.09px;}
#t1v_153{left:618px;bottom:482px;letter-spacing:0.04px;word-spacing:-0.03px;}
#t1w_153{left:1109px;bottom:490px;letter-spacing:-0.01px;}
#t1x_153{left:1132px;bottom:482px;letter-spacing:-0.03px;}
#t1y_153{left:618px;bottom:459px;letter-spacing:0.16px;word-spacing:0.16px;}
#t1z_153{left:618px;bottom:436px;letter-spacing:0.15px;word-spacing:0.04px;}
#t20_153{left:618px;bottom:413px;letter-spacing:0.1px;word-spacing:0.08px;}
#t21_153{left:618px;bottom:372px;letter-spacing:0.33px;word-spacing:-0.14px;}
#t22_153{left:618px;bottom:343px;letter-spacing:0.03px;word-spacing:-0.59px;}
#t23_153{left:618px;bottom:320px;letter-spacing:0.18px;word-spacing:0.01px;}
#t24_153{left:618px;bottom:297px;letter-spacing:0.05px;word-spacing:-1.1px;}
#t25_153{left:618px;bottom:273px;letter-spacing:0.12px;word-spacing:0.07px;}
#t26_153{left:618px;bottom:250px;letter-spacing:0.06px;word-spacing:0.13px;}
#t27_153{left:618px;bottom:227px;letter-spacing:0.08px;word-spacing:0.1px;}
#t28_153{left:618px;bottom:188px;letter-spacing:0.04px;word-spacing:-1.08px;}
#t29_153{left:618px;bottom:165px;letter-spacing:0.09px;word-spacing:0.1px;}
#t2a_153{left:618px;bottom:141px;letter-spacing:0.13px;word-spacing:0.06px;}
#t2b_153{left:618px;bottom:118px;letter-spacing:0.09px;word-spacing:0.09px;}
#t2c_153{left:618px;bottom:95px;letter-spacing:0.05px;word-spacing:0.13px;}
#t2d_153{left:618px;bottom:72px;letter-spacing:0.21px;word-spacing:-0.02px;}
#t2e_153{left:700px;bottom:72px;letter-spacing:0.28px;}
#t2f_153{left:774px;bottom:72px;letter-spacing:0.12px;word-spacing:0.07px;}
#t2g_153{left:23px;bottom:915px;letter-spacing:-0.14px;}

.s0_153{font-size:10px;font-family:ArialMT_5tg;color:#000;}
.s1_153{font-size:6px;font-family:ArialMT_5tg;color:#000;}
.s2_153{font-size:28px;font-family:Arial-BoldMT_5te;color:#000;}
.s3_153{font-size:17px;font-family:Arial-BoldMT_5te;color:#000;}
.s4_153{font-size:17px;font-family:ArialMT_5tg;color:#000;}
.s5_153{font-size:17px;font-family:Arial-ItalicMT_kb;color:#000;}
.s6_153{font-size:11px;font-family:ArialMT_5tg;color:#000;}
.s7_153{font-size:16px;font-family:Arial-BoldItalicMT_kg;color:#000;}
.s8_153{font-size:11px;font-family:Helvetica, Arial, sans-serif;color:#000;}
</style>
<style id="fonts153" type="text/css" >

@font-face {
	font-family: Arial-BoldItalicMT_kg;
	src: url("fonts/Arial-BoldItalicMT_kg.woff") format("woff");
}

@font-face {
	font-family: Arial-BoldMT_5te;
	src: url("fonts/Arial-BoldMT_5te.woff") format("woff");
}

@font-face {
	font-family: Arial-ItalicMT_kb;
	src: url("fonts/Arial-ItalicMT_kb.woff") format("woff");
}

@font-face {
	font-family: ArialMT_5tg;
	src: url("fonts/ArialMT_5tg.woff") format("woff");
}

</style>
<div id="pg153Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg153" style="-webkit-user-select: none;"><object width="1210" height="935" data="153/153.svg" type="image/svg+xml" id="pdf153" style="width:1210px; height:935px; z-index: 0;"></object></div>
<div class="text-container"><span id="t1_153" class="t s0_153">Version 4.2024 © 2024 National Comprehensive Cancer Network </span>
<span id="t2_153" class="t s1_153">© </span>
<span id="t3_153" class="t s0_153">(NCCN </span>
<span id="t4_153" class="t s1_153">© </span>
<span id="t5_153" class="t s0_153">), All rights reserved. NCCN Guidelines </span>
<span id="t6_153" class="t s1_153">® </span>
<span id="t7_153" class="t s0_153">and this illustration may not be reproduced in any form without the express written permission of NCCN. </span>
<span id="t8_153" class="t s2_153">NCCN Guidelines Version 4.2024 </span>
<span id="t9_153" class="t s2_153">Head and Neck Cancers </span>
<span id="ta_153" class="t s3_153">MS-12 </span>
<span id="tb_153" class="t s4_153">respectively; HR, 0.75, 95% CI, 0.57–0.98; </span><span id="tc_153" class="t s5_153">P </span><span id="td_153" class="t s4_153">= .035) were all significantly </span>
<span id="te_153" class="t s4_153">greater in the docetaxel arm compared to the RT alone arm (39% treated </span>
<span id="tf_153" class="t s4_153">postoperatively). </span>
<span id="tg_153" class="t s6_153">140 </span>
<span id="th_153" class="t s4_153">There was a significantly greater incidence of some </span>
<span id="ti_153" class="t s4_153">grade 3 or above adverse events (mucositis, odynophagia, and </span>
<span id="tj_153" class="t s4_153">dysphagia) in the docetaxel arm. Study results support use of docetaxel as </span>
<span id="tk_153" class="t s4_153">a radiosensitizer for patients undergoing adjuvant treatment who are </span>
<span id="tl_153" class="t s4_153">cisplatin ineligible. </span>
<span id="tm_153" class="t s4_153">In the randomized phase II RTOG-0234 trial, two regimens in patients with </span>
<span id="tn_153" class="t s4_153">stage III and IV SCCHN were compared: 1) adjuvant chemoradiotherapy </span>
<span id="to_153" class="t s4_153">with cetuximab and docetaxel; and 2) adjuvant chemoradiotherapy with </span>
<span id="tp_153" class="t s4_153">cetuximab and weekly cisplatin (</span><span id="tq_153" class="t s5_153">N </span><span id="tr_153" class="t s4_153">= 238). </span>
<span id="ts_153" class="t s6_153">141 </span>
<span id="tt_153" class="t s4_153">After a median follow-up of </span>
<span id="tu_153" class="t s4_153">4.4 years, patients randomized to receive docetaxel experienced a 31% </span>
<span id="tv_153" class="t s4_153">reduction in DFS failure rate (HR, 0.69; 95% CI, 0.50–0.96; </span><span id="tw_153" class="t s5_153">P </span><span id="tx_153" class="t s4_153">= .01), and a </span>
<span id="ty_153" class="t s4_153">44% reduction in mortality (HR, 0.56; 95% CI, 0.39–0.82; </span><span id="tz_153" class="t s5_153">P </span><span id="t10_153" class="t s4_153">= .001). The </span>
<span id="t11_153" class="t s4_153">randomized phase II/III RTOG 1216 trial is continuing to investigate </span>
<span id="t12_153" class="t s4_153">docetaxel/cetuximab with postoperative RT, compared to cisplatin or </span>
<span id="t13_153" class="t s4_153">docetaxel with postoperative RT (NCT01810913). For patients with high- </span>
<span id="t14_153" class="t s4_153">risk adverse pathologic features following surgery (ie, extranodal </span>
<span id="t15_153" class="t s4_153">extension and/or positive margins) who are ineligible for platinum therapy, </span>
<span id="t16_153" class="t s4_153">docetaxel/cetuximab is a category 2B option for postoperative systemic </span>
<span id="t17_153" class="t s4_153">therapy/RT. </span>
<span id="t18_153" class="t s7_153">Surgery for Relapsed/Refractory Disease </span>
<span id="t19_153" class="t s4_153">Patients with advanced carcinoma (any T, N2–3) who undergo nonsurgical </span>
<span id="t1a_153" class="t s4_153">treatment, such as concurrent chemotherapy and RT, need very close </span>
<span id="t1b_153" class="t s4_153">follow-up both to evaluate for local recurrence and to assess for ipsilateral </span>
<span id="t1c_153" class="t s4_153">or contralateral neck recurrence (see </span><span id="t1d_153" class="t s5_153">Follow-up Recommendations </span><span id="t1e_153" class="t s4_153">in the </span>
<span id="t1f_153" class="t s4_153">NCCN Guidelines for Head and Neck Cancers). For patients who do not </span>
<span id="t1g_153" class="t s4_153">have a complete clinical response to systemic therapy/RT, surgery is </span>
<span id="t1h_153" class="t s4_153">recommended as indicated. However, all panel members emphasized that </span>
<span id="t1i_153" class="t s4_153">it may be difficult to detect local or regional recurrence due to </span>
<span id="t1j_153" class="t s4_153">radiation-related tissue changes, and this may result in a delayed </span>
<span id="t1k_153" class="t s4_153">diagnosis of persistent or recurrent disease. </span>
<span id="t1l_153" class="t s4_153">Panel members also emphasized the increased risk of complications when </span>
<span id="t1m_153" class="t s4_153">surgery in patients with relapsed/refractory disease is attempted. Some of </span>
<span id="t1n_153" class="t s4_153">these patients may require microvascular free tissue transfer to </span>
<span id="t1o_153" class="t s4_153">reconstruct the surgical defect at the primary site. The patients undergoing </span>
<span id="t1p_153" class="t s4_153">neck dissection may develop complications related to delayed wound </span>
<span id="t1q_153" class="t s4_153">healing, skin necrosis, neuropathy, fibrosis, pain, swallowing difficulties, </span>
<span id="t1r_153" class="t s4_153">and carotid exposure. Laryngectomy may be indicated to obtain clear </span>
<span id="t1s_153" class="t s4_153">surgical margins or to prevent aspiration (eg, in patients with advanced </span>
<span id="t1t_153" class="t s4_153">oropharyngeal cancer). After laryngectomy for relapsed/refractory disease, </span>
<span id="t1u_153" class="t s4_153">patients may have a higher incidence of pharyngocutaneous fistula, </span>
<span id="t1v_153" class="t s4_153">pharyngeal and stomal stenosis, and other wound complications. </span>
<span id="t1w_153" class="t s6_153">142 </span>
<span id="t1x_153" class="t s4_153">Flaps </span>
<span id="t1y_153" class="t s4_153">may be advantageous (either a free flap reconstruction of the </span>
<span id="t1z_153" class="t s4_153">laryngopharyngeal defect, or a myocutaneous flap to buttress the suture </span>
<span id="t20_153" class="t s4_153">line if the pharynx can be closed primarily). </span>
<span id="t21_153" class="t s3_153">Head and Neck Radiation Therapy </span>
<span id="t22_153" class="t s4_153">RT for H&amp;N cancers is increasingly complex. The availability and technical </span>
<span id="t23_153" class="t s4_153">precision of techniques such as intensity-modulated RT (IMRT) or </span>
<span id="t24_153" class="t s4_153">intensity-modulated proton therapy (IMPT) have each markedly increased. </span>
<span id="t25_153" class="t s4_153">However, a thorough understanding of the natural history, anatomy, </span>
<span id="t26_153" class="t s4_153">clinical circumstances, and imaging of specific disease conditions </span>
<span id="t27_153" class="t s4_153">continues to guide the use of radiation as primary or adjuvant treatment. </span>
<span id="t28_153" class="t s4_153">Principles regarding radiation prescriptions and techniques as described in </span>
<span id="t29_153" class="t s4_153">the NCCN Guidelines for Head and Neck Cancers are not all-inclusive. </span>
<span id="t2a_153" class="t s4_153">The planning and delivery of RT are rapidly evolving, and these </span>
<span id="t2b_153" class="t s4_153">technological advances provide much opportunity for variations and </span>
<span id="t2c_153" class="t s4_153">individualization in targeting and dose delivery, obviating traditional </span>
<span id="t2d_153" class="t s4_153">notions of </span><span id="t2e_153" class="t s5_153">standard </span><span id="t2f_153" class="t s4_153">fields and targets. Guidelines from the American </span>
<span id="t2g_153" class="t s8_153">Printed by Fredd Merc on 8/29/2024 4:45:54 AM. For personal use only. Not approved for distribution. Copyright © 2024 National Comprehensive Cancer Network, Inc., All Rights Reserved. </span></div>

</div>
</body>
</html>
